Federal Trade Commission Takes Action Against 10 Drugmakers Over Patent Claims
Tuesday, 30 April 2024, 17:48
FTC Challenges 'Junk' Patents in Drug Industry
The Federal Trade Commission has recently targeted 10 major drugmakers, including Novo Nordisk and AstraZeneca, questioning the validity of their patents.
This move could have significant implications for the pharmaceutical industry, potentially reshaping the competitive landscape.
The actions from the FTC highlight the ongoing scrutiny over patent practices and the need for increased transparency.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.